Zacks Investment Research
24 Sept 2026, 17:51 UTC · 1h ago
Verdict
Headline takes no side. We score GKOS +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 74% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Epioxa generated approximately $11 million in sales during the second quarter, its first full quarter of commercial availability.
Priced inanalysis of Q2 results reported earlier
So whatInitial traction against a 125 million commercial lives access pathway suggests a steep revenue ramp for FY2027.
More positive than 86% of claims this week
Eligible early commercial patients are successfully undergoing iDose re-administration as initial therapy wears off.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Priced inanalysis of management reports
More positive than 77% of claims this week
Glaukos's O2N treatment-center network currently serves roughly 85% of the U.S. population, with a pipeline to reach approximately 95%.
Priced inanalysis of current network status
So whatClosing the 10% coverage gap provides a tangible tailwind for market penetration in underserved regions.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 74% of ticker scores this week
The company shows strong growth prospects, a positive earnings surprise, and a potential recurring revenue stream from iDose re-administration.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
+1.1%
Price agrees with the score
$155.25 vs $153.49 close before publication (Sep 23) · not market-adjusted
GKOS chart →
